Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

807191

registered interest
date	15/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the commercial agreement announced by NHS England on 9 November 2017, what the timetable is for NICE to issue final guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer.
tabling member constituency	North Warwickshire
tabling member printed	Craig Tracey
uin	119837
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>The timetable for the National Institute for Health and Care Excellence’s (NICE) guidance on Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel for HER2 positive metastatic or locally recurrent unresectable breast cancer is still to be confirmed. Perjeta remains available to new and existing National Health Service patients through the Cancer Drugs Fund pending NICE’s final guidance.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 11:38:14 answering member 4067 label Biography information for Steve Brine
tabling member	4509 label Biography information for Craig Tracey

782789

registered interest
date	02/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of the Cancer Transformation Funding in 2017-18 has been provided to Cancer Alliances; and whether any remaining funding will be rolled over into the budget for 2018-19 in order to ensure that NHS England meets its cancer strategy funding commitments.
tabling member constituency	North Warwickshire
tabling member printed	Craig Tracey
uin	111229
answer	answer is ministerial correction date of answer 08/11/2017 answer text <p>All Cancer Alliances have a delivery plan in place for the Cancer Taskforce recommendations. £200 million was committed in transformation funding to support Alliances with a particular focus on driving improvements in early diagnosis and quality of life over this and the next financial year. Cancer Alliances are starting to receive Transformation funding in phases over the course of this year based on the readiness of systems to take on the transformation work and the strength of their plans. The full investment in delivering the Cancer Taskforce strategy is set out in the One Year On report, and most recently in the Progress Report for 2016/17 published in October 2017 and is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/11/2017 17:23:44 answering member 4067 label Biography information for Steve Brine
tabling member	4509 label Biography information for Craig Tracey